Travere Therapeutics, Inc. (TVTX) Q3 2025 Earnings Call Transcript [Seeking Alpha]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Seeking Alpha
Nivi Nehra - Vice President of Corporate Communications & Investor Relations Eric Dube - President, CEO & Director Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - Chief Financial Officer William Rote - Chief Research Officer Conference Call Participants Joseph Schwartz - Leerink Partners LLC, Research Division Laura Chico - Wedbush Securities Inc., Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Yigal Nochomovitz - Citigroup Inc. Exchange Research Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Maurice Raycroft - Jefferies LLC, Research Division Jason Zemansky - BofA Securities, Research Division Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- Travere Therapeutics (NASDAQ:TVTX) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TVTX&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StMarketBeat
- Travere Therapeutics (NASDAQ:TVTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $47.00 price target on the stock.MarketBeat
- Why IBD 50's No. 3 Stock, Travere Therapeutics, Has Doubled In 2025 [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics: Thriving Kidney Franchise Set To Soar On January PDUFA [Seeking Alpha]Seeking Alpha
- Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally [Yahoo! Finance]Yahoo! Finance
TVTX
Earnings
- 10/30/25 - Beat
TVTX
Sec Filings
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- 11/14/25 - Form SCHEDULE
- TVTX's page on the SEC website